Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381661 | 1.00 | MAOB (0.54) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL1577000 | 0.92 | MAOB (0.48) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL4379433 | 0.92 | MAOB (0.48) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL3697792 | 0.92 | MAOB (0.48) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL7106133 | 0.90 | APP (0.50) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL7106127 | 0.90 | APP (0.50) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL23962525 | 0.89 | MMP3 (0.52) | MAOBAKR1B10AKR1B1CA12CA4 | |
| SCHEMBL4256257 | 0.85 | MAOB (0.67) | MAOBCA1CA2ARG2CYP3A4 | |
| SCHEMBL163963 | 0.85 | MAOB (0.67) | MAOBCA1CA2ARG2CYP3A4 | |
| SCHEMBL1892917 | 0.85 | MAOB (0.67) | MAOBCA1CA2ARG2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109730071-A | A kind of composition of medicine and preparation method thereof for preventing and treating vegetable sprout term damping-off | 丰县嘉诺农业科技发展有限公司 | 2019-05-10 | — | — | CN | claimed |
| US-4012529-A | SUBSTITUTED 4-(3-PHENYLPROPENYLIDENE)-2,5-CYCLOHEXADIENEONES AS LARVICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1977-03-15 | — | — | US | claimed |
| EP-1670485-A4 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | RESVERLOGIX CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670485-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034960-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | MAOB 183/4885AKR1B10 494/4885AKR1B1 173/4885 |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | TOE1, ATF1, ELF3 | MAOB 3513/4885AKR1B10 2970/4885AKR1B1 1796/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | MAOB 222/4885AKR1B10 504/4885AKR1B1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.